Equillium, Bluejay Diagnostics, and Entero Therapeutics are the 3 Penny Stocks to watch on August 12, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are defined as stocks that trade at or below $5 per share and have a market capitalization below $300 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Penny Stock Screener helps investors scan stocks based on numerous parameters, including Sector, Price Target Upside, Smart Score, Analyst Consensus, Dollar Volume, and Price Change.
We leveraged the tool to pick the top three penny stocks with the highest Dollar Volume as of the close on August 11, 2025. Simply put, Dollar Volume is the number of shares traded on a particular day multiplied by the day’s share price.
Equillium (EQ) – Equillium is a clinical-stage biotechnology company focused on developing novel treatments for severe autoimmune and inflammatory diseases. On August 11, EQ had a Dollar Volume of $21.45 million, while its stock price skyrocketed by nearly 79%.
Yesterday, Equillium announced a $50 million private placement, which comes in two payments: an upfront payment of $30 million in exchange for 52.6 million EQ shares, and another $20 million for 35.1 million shares if certain milestones are met. It expects the initial financing to extend its cash runway through 2027. The proceeds will be used to progress Equillium’s development of lead drug candidate EQ504, as well as for working capital and general corporate purposes.
Bluejay Diagnostics (BJDX) – Bluejay Diagnostics is a late-stage, pre-revenue diagnostics company focused on developing products for the triage, diagnosis, and monitoring of disease progression in the U.S. Yesterday, BJDX had a Dollar Volume of $187.30 million, accompanied by a stock price surge of 34.3%.
On August 7, Bluejay Diagnostics provided a second quarter business update. The company noted that initial patient enrollment in the SYMON-II clinical study had begun, which is crucial for its Symphony platform. Bluejay also stated that it will require additional capital through 2027 to support manufacturing readiness, clinical trials, and regulatory activities, and that it is actively exploring strategic and institutional financing avenues to meet these goals.
Entero Therapeutics (ENTO) – Entero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatment for gastrointestinal diseases. On Monday, ENTO had a Dollar Volume of $183.32 million, while its stock price surged by more than 66%.
Entero announced a $3 million private placement, consisting of 4,878,841 pre-funded warrants and 9,757,682 common warrants to purchase shares of ENTO stock, priced at-the-market. The company intends to use the proceeds from this offering for general corporate purposes and working capital.
To find more penny stocks like these, you can take a look at TipRanks’ Penny Stock Screener tool. It shows a list of all penny stocks, their price movement, and other vital data.